IBRX News

Pomerantz LLP Notifies Investors of Class Action Filing Against ImmunityBio, Inc. – IBRX

Final IBRX Deadline Reminder: May 26, 2026 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP

IBRX 4-DAY DEADLINE ALERT: ImmunityBio (IBRX) Investors Face Losses Amid FDA Warning Regarding Unsupported Cancer Treatment Claims – Hagens Berman

ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

IBRX CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 Ready to Announce with Confidence?

ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA ® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS

IBRX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!

Class Action Lawsuit Reminder from Pomerantz LLP for Shareholders of ImmunityBio, Inc. – IBRX

TUESDAY INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

IBRX DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by The Firm - IBRX